Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.

@article{Jones1993AcuteLI,
  title={Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.},
  author={R Barry Jones and Steve Matthes and Elizabeth J Shpall and John Herbert Fisher and Salomon Marcello Stemmer and Christopher Dufton and Julia Stephens and Scott I. Bearman},
  journal={Journal of the National Cancer Institute},
  year={1993},
  volume={85 8},
  pages={640-7}
}
BACKGROUND Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease. This therapy is being used in a cooperative intergroup phase III clinical trial. In the cyclophosphamide-cisplatin-BCNU regimen, cyclophosphamide and BCNU, but not cisplatin, have been reported to cause acute lung… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Pharmacological considerations in high-dose chemotherapy

Cancer Chemotherapy and Pharmacology • 1997
View 4 Excerpts
Highly Influenced

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2004
View 1 Excerpt

Similar Papers

Loading similar papers…